Perdoceo Education to acquire South University for up to $204M
Source: Investing.com

Perdoceo Education agreed to acquire South University for approximately $130 million-$140 million in cash at closing, plus $18 million of deferred payments and up to $56 million in EBITDA-based earn-outs. South University generated approximately $291 million of unaudited 2025 revenue and $34 million of adjusted operating income, serving roughly 10,500 students across 11 campuses and online programs. Perdoceo expects the deal, funded with cash on hand, to close as early as April 2027 and be immediately accretive to adjusted operating income; it reaffirmed 2026 adjusted operating income guidance of $258 million-$263 million.
Analysis
The market should assign limited near-term value to this transaction until accreditor and Department of Education approvals are visible; the closing timetable leaves PRDO exposed to a long regulatory-option period rather than an immediate earnings catalyst. That said, the contingent consideration structure materially limits downside if enrollment, retention, or program-level profitability underperform, while the acquired operating-income base could add roughly 13% to PRDO's current operating-income run rate before any shared-services synergies. The key analytical issue is whether the initial cash consideration implies a sustainable low-single-digit multiple of operating profit rather than a temporary peak in healthcare-program economics.
The strategic value is less about generic postsecondary enrollment and more about capacity in licensed clinical programs, where seat supply is constrained by clinical-placement availability, faculty shortages, and state approvals. If PRDO can improve lead conversion, online-course utilization, and back-office costs without weakening student outcomes, margins can expand; conversely, clinical programs have less flexibility to cut costs than PRDO's legacy online-heavy operations. Adtalem Global Education (ATGE), Universal Technical Institute (UTI), and nursing-school operators become relevant comparables: PRDO may gain a healthcare-growth multiple only after it demonstrates that its compliance infrastructure can support regulated professional programs.
Consensus may over-credit stated accretion while underweighting the for-profit conversion risk. Title IV eligibility, gainful-employment metrics, state professional-licensure rules, and accreditation conditions can each affect enrollment economics before closing or shortly thereafter. A failed approval or material enrollment decline would likely leave PRDO with a temporarily stranded growth narrative, but the delayed cash outlay and earn-out design cap balance-sheet damage; this is therefore a milestone-driven equity catalyst, not a reason to underwrite FY2026 estimates higher today.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.58
Ticker Sentiment
Key Decisions for Investors
- Maintain or initiate a modest long PRDO only on weakness ahead of the next regulatory/accreditor milestone; use a 12-18 month horizon rather than positioning for immediate FY2026 estimate revisions. The upside case is a healthcare-program re-rating plus 2027 earnings accretion, while the primary risk is approval delay beyond the contractual outside date.
- Do not capitalize the full earn-out in base-case valuation. Underwrite only the initial consideration until PRDO discloses enrollment trends, retention, student-outcome metrics, and operating margins for the acquired business; treat earn-out achievement as upside rather than synergy certainty.
- Use ATGE as the closest listed relative-value monitor. If PRDO's EV/forward operating income remains at a material discount after approvals while management confirms stable enrollment and no adverse Title IV or accreditation conditions, consider long PRDO versus short ATGE as a 6-12 month convergence trade; avoid the pair if ATGE's healthcare enrollment growth is materially stronger.
- Set a thesis-stop alert around any adverse accreditor action, Department of Education restriction, or evidence that healthcare-program enrollment declines mid-single digits or more. Those outcomes would challenge both the acquisition economics and the premise that PRDO can earn a higher-quality education-services multiple.
More News
- Exclusive-Kimberly-Clark readies asset sales in bid for EU nod for Kenvue deal, sources say
- JPMorgan double upgraded a data center stock that struck a deal with Nvidia earlier this year
- ASML examining ways it can make more than 110 EUV tools in 2028, JPMorgan says
- Google wants Spirit Airlines’ data. Micro1 wants to pay more.
- Novo Nordisk rebrands as ’Novo’, announces cultural reset
- OpenAI’s IPO wait grows longer as AI safety fears mount